다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Clinical nuclear medicine, v.42 no.4, 2017년, pp.250 - 257
Bund, Caroline (From the *Service de Biophysique et Mé) , Heimburger, Céline (decine Nuclé) , Imperiale, Alessio (aire, Hô) , Lhermitte, Benoît (pitaux Universitaires de Strasbourg) , Chenard, Marie-Pierre (†ICube, Université) , Lefebvre, François (de Strasbourg) , Kremer, Stéphane (‡Fé) , Proust, François (dé) , Namer, Izzie-Jacques (ration de Mé)
BACKGROUND: Primary brain tumor grading is crucial to rapidly determine the therapeutic impact and prognosis of a brain tumor as well as the tumors’ aggressiveness profile. On magnetic resonance imaging, high-grade tumors are usually responsible for blood -brain barrier breakdowns, which result in tumor enhancement. However, this is not always the case. The main objective of this study was to evaluate the diagnostic value of FDOPA PET in the assessment of primary brain tumor aggressiveness with no contrast enhancement on MRI. METHODS: Fifty-three patients were prospectively included: 35 low-grade and 18 high-grade histologically proven gliomas, with no contrast enhancement. Each patient underwent static PET acquisitions at 30 minutes. All patients had MRSI with measurements of different metabolites ratio. RESULTS: FDOPA was useful in the subgroup of low-grade gliomas, discriminating between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma (P < 0.01). An optimal threshold of the maximum standardized uptake value at 30 minutes (SUVmax (T/N)30) = 2.16 to discriminated low- from high-grade gliomas with a sensitivity of 60%, specificity of 100%, PPV of 100%, and NPV of 83.33% (P < 0.01). The nCho/Cr and nCho/NAA ratios were significantly higher in high- than in low-grade gliomas (P < 0.03 and P < 0.04, respectively). A significant positive correlation between MRSI ratios and SUVmax was found. CONCLUSION: Including data from amino acid metabolism used alone or in association with MRSI allows us to discriminate between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma and between low- and high-grade gliomas with no contrast enhancement on MRI.
Acta Neuropathol Louis 114 97 2007 10.1007/s00401-007-0243-4 The 2007 WHO classification of tumours of the central nervous system
Neurosurgery Daumas-Duport 23 545 1988 10.1227/00006123-198811000-00002 Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases
J Neurooncol Daumas-Duport 34 61 1997 10.1023/A:1005759220434 Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria
Cancer Daumas-Duport 62 2152 1988 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T Grading of astrocytomas. A simple and reproducible method
Neurol Res Chaichana 31 931 2009 10.1179/174313209X395454 Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature
Neurology Scott 59 947 2002 10.1212/WNL.59.6.947 How often are nonenhancing supratentorial gliomas malignant? A population study
Surg Neurol Ginsberg 49 436 1998 10.1016/S0090-3019(97)00360-1 The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series
Lancet Neurol Dhermain 9 906 2010 10.1016/S1474-4422(10)70181-2 Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Biochem Pharmacol Yee 62 1409 2001 10.1016/S0006-2952(01)00787-0 Blood-brain barrier and neuronal membrane transport of 6-[18 F]fluoro-L-DOPA
Eur J Nucl Med Mol Imaging Kim 32 52 2005 10.1007/s00259-004-1598-6 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET
Clin Nucl Med Tripathi 34 878 2009 10.1097/RLU.0b013e3181becfe0 Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas
J Nucl Med Fueger 51 1532 2010 10.2967/jnumed.110.078592 Correlation of 6-18 F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas
J Neurosurg Shinozaki 114 1640 2011 10.3171/2010.11.JNS10553 Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography
J Neurooncol Stockhammer 88 205 2008 10.1007/s11060-008-9551-3 Correlation of 18 F-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas
J Nucl Med Chen 47 904 2006 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy
J Nucl Med Schiepers 48 1651 2007 10.2967/jnumed.106.039321 18 F-FDOPA kinetics in brain tumors
Lancet van den Bent 366 985 2005 10.1016/S0140-6736(05)67070-5 Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
N Engl J Med Stupp 352 987 2005 10.1056/NEJMoa043330 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
Br J Radiol Fan 79 652 2006 10.1259/bjr/25349497 Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?
J Neurosurg McKnight 106 660 2007 10.3171/jns.2007.106.4.660 Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas
Eur J Nucl Med Mol Imaging Sasajima 31 1244 2004 10.1007/s00259-004-1512-2 Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines
Eur J Radiol Ledezma 71 242 2009 10.1016/j.ejrad.2008.04.018 18 F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience
Seizure Rossi 19 470 2010 10.1016/j.seizure.2010.07.001 Early presentation of de novo high grade glioma with epileptic seizures: electroclinical and neuroimaging findings
Neurosurg Rev Cohen-Gadol 27 281 2004 10.1007/s10143-004-0346-5 Non-enhancing de novo glioblastoma: report of two cases
J Neurol Neurosurg Psychiatry Rosenberg 76 1686 2005 10.1136/jnnp.2004.051607 [11C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms
J Nucl Med Phi 51 728 2010 10.2967/jnumed.109.070920 Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using 18 F-FDG and 11C-methionine pet
Neuro-Oncol Rheims 16 1417 2014 10.1093/neuonc/nou022 Accuracy of distinguishing between dysembryoplastic neuroepithelial tumors and other epileptogenic brain neoplasms with [11C]methionine PET
Eur J Nucl Med Mol Imaging Becherer 30 1561 2003 10.1007/s00259-003-1259-1 Brain tumour imaging with PET: a comparison between [18 F]fluorodopa and [11C]methionine
Clin Nucl Med Janvier 40 e429 2015 10.1097/RLU.0000000000000897 Correlation of SUV-derived indices with tumoral aggressiveness of gliomas in static 18 F-FDOPA PET: use in clinical practice
J Nucl Med Heiss 37 1180 1996 F-Dopa as an amino acid tracer to detect brain tumors
Neuroradiology Tamiya 42 333 2000 10.1007/s002340050894 Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.